Skip to content
Create account to build your panelHelp me choose

Menopause Hormone Therapy (HRT): Which Lab Tests Matter, and Which Don't

By the EllaDx team · Updated November 5, 2026 · 11 min read

For education only, not a diagnosis. Talk to your clinician about your results.

Two women talking on a sofa in a bright living room
← Back to Journal

Hormone replacement therapy (HRT) has become one of the most talked-about topics in women's health, and for good reason. It's the most effective treatment for hot flashes and night sweats, and for the genitourinary syndrome of menopause (North American Menopause Society, 2022). But you may hear that you need a long list of hormone tests first. The guidance we reviewed points somewhere else: to your symptoms, your health history and your risks.

Whether you're exploring HRT for the first time or already on therapy, this guide covers which lab tests can help, which add little, and why.

What Guides HRT Decisions

Menopause hormone therapy isn't one-size-fits-all. Its risks differ by type, dose, how long you use it, how you take it, when you start, and whether a progestogen is used. The North American Menopause Society says treatment should be individualized, with periodic review of benefits and risks. For women under 60 or within 10 years of menopause onset who have no contraindications, it says the balance is favorable for bothersome hot flashes and preventing bone loss. For women who start later, or after 60, it appears less favorable (North American Menopause Society, 2022).

Before starting, the Endocrine Society says clinicians should screen women for cardiovascular and breast cancer risk, and recommend the most appropriate therapy based on that risk (Stuenkel et al., 2015). In trials, the added risk of stroke, blood clots and, with one combined therapy, breast cancer was about 1 extra case per 1,000 women a year (Crandall et al., 2023).

We found no guideline summary that sets blood hormone targets for HRT, so we don't list any here. Labs differ too. Ask your clinician how they plan to track your treatment.

Lab Tests to Discuss Before Starting HRT

1. Estradiol (E2)

Estradiol is the main estrogen your ovaries make. Perimenopause brings wide hormonal fluctuations (Santoro et al., 2021), and steroid hormones can change in erratic, less predictable ways once cycles turn irregular (Hale et al., 2009). So one estradiol result can miss the bigger picture.

2. FSH (Follicle-Stimulating Hormone)

FSH can rise as ovarian function declines, and it's one of the supporting markers used to stage reproductive aging (Hale et al., 2014). But staging leans on bleeding patterns (Harlow et al., 2012), and menopause is defined after the fact, 12 months after your final period (Mangione et al., 2022). Menopause typically occurs between 45 and 56 (Crandall et al., 2023). If your periods stop well before that, see your clinician.

3. Progesterone

If you have a uterus, a Cochrane review says hormone therapy should include a progestogen along with estrogen, to reduce the risk of endometrial hyperplasia (Furness et al., 2012). That advice rests on whether you have a uterus, not on a blood level.

4. Total and Free Testosterone

Testosterone can fall with age, and the steepest drop can come in the earlier reproductive years. One small study estimated that a woman of 40 had about half the level of a woman of 21 (Zumoff et al., 1995). A study of 1,423 women found no separate effect of natural menopause on androgen levels (Davison et al., 2005).

An Endocrine Society guideline recommends against diagnosing androgen deficiency in healthy women, because it found no data linking androgen levels with specific symptoms (Wierman et al., 2014). So low energy, brain fog or muscle loss can't be pinned on a testosterone number. If low desire that causes you distress is the concern, a guideline says a total testosterone level shouldn't be used to diagnose it, but can be a baseline if treatment starts (Parish et al., 2021).

5. TSH

A guideline names serum TSH as the main screening test for primary thyroid problems in most outpatients (Garber et al., 2012). In a study of 3,242 women aged 42 to 52, about 1 in 10 had a TSH outside the usual range, but TSH was not linked with menopause stage or most menopause symptoms (Sowers et al., 2003). The US Preventive Services Task Force found too little evidence to weigh the benefits and harms of screening adults with no symptoms (LeFevre et al., 2015). If you have symptoms that may point to a thyroid problem, ask your clinician about testing.

6. Heart and Metabolic Health

The menopause transition can bring changes in body composition, lipids and blood vessel health that can increase heart disease risk (El Khoudary et al., 2020), and the risk of type 2 diabetes can rise too (Slopien et al., 2018). Your clinician may check:

  • Lipid panel - total cholesterol, LDL, HDL, triglycerides
  • Fasting glucose or HbA1c - screening is recommended for adults aged 35 to 70 with overweight or obesity (Davidson et al., 2021)
  • Blood pressure - part of a cardiovascular risk check

Hormone therapy isn't a way to protect your heart. The Women's Health Initiative trials do not support its use for chronic disease prevention, though it's appropriate for symptom management in some women (Manson et al., 2013). The US Preventive Services Task Force recommends against it for preventing chronic conditions (Mangione et al., 2022). It has been linked with fewer cases of diabetes (Manson et al., 2013), but that's no reason to start it for that purpose.

Follow-Up While on HRT

Once you've started HRT, follow-up is about how your symptoms respond, any side effects, and whether the benefits still outweigh the risks. Treatment should include periodic reevaluation, and longer use should be for documented reasons such as ongoing hot flashes, with shared decision-making (North American Menopause Society, 2022). Your clinician can tell you when to come back.

Route-Specific Considerations

How you take estrogen can matter more for safety than for symptom relief. Oral and transdermal estrogen have similar efficacy (Crandall et al., 2023).

Oral estrogen:

  • A review found that oral estrogen-only products raised the risk of blood clots in the veins to about 1.5 times the risk without them (Scarabin, 2018)

Transdermal estrogen (patches, gels, creams):

  • In the same review, transdermal estrogen did not increase that risk, including when used with micronized progesterone, though some other progestogens raised it (Scarabin, 2018)
  • An expert guide says transdermal estradiol is preferred for women with type 2 diabetes who also have cardiovascular risk factors (Slopien et al., 2018)

Pellets and compounded hormones:

  • Compounded bioidentical hormones lack data on how they act in the body, on safety and on efficacy, and pellets can give doses above natural levels, which raises more safety concerns (Pinkerton, 2022)
  • Compounding pharmacies may use saliva tests to customize hormones, but salivary levels aren't equivalent to free hormone levels in blood (Stanczyk et al., 2021)

Ongoing Care

Your usual preventive care continues while you're on HRT, including the tests your clinician advises for your age and risks.

Symptoms to Bring to Your Clinician

Your symptoms can tell a lot of the story. Tell your clinician about these:

  • Persistent hot flashes or night sweats - your treatment may need a review
  • Breast tenderness or bloating - your clinician can review your treatment with you
  • Mood symptoms (anxiety, irritability, low mood) - get help, and don't wait for lab results
  • Low desire that causes you distress - testosterone has helped some postmenopausal women (Islam et al., 2019), so ask whether it fits your situation
  • Fatigue and brain fog - ask what else may be going on, including your thyroid
  • Unscheduled bleeding - this can affect up to 40% of HRT users (Manley et al., 2024). Always report it. In a large review, 9% of women with postmenopausal bleeding had endometrial cancer, and most did not (Clarke et al., 2018)

Get emergency care for chest pain, sudden shortness of breath, a swollen and painful leg, or signs of a stroke such as face drooping or arm weakness. Hormone therapy can raise the risk of blood clots and stroke (Crandall et al., 2023).

The Bottom Line

HRT is the most effective treatment for hot flashes and night sweats (North American Menopause Society, 2022), and it can make a real difference. The decision rests on your symptoms, age, time since menopause, health history and risks, more than on a hormone number. Heart and metabolic checks can help, and other tests depend on your symptoms. If a test is suggested, ask what the result would change.

Take the Quiz

Want to see which tests may fit your symptoms? Take our free Biomarker Quiz to get personalized lab test recommendations based on your symptoms. It takes about 3 minutes, and it can give you a starting point for talking with your clinician about HRT.

References

  • The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. PMID 35797481
  • Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368. PMID 24084921
  • Scarabin, P. Y. (2018). Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric, 21(4), 341-345. PMID 29570359
  • Slopien, R., et al. (2018). Menopause and diabetes: EMAS clinical guide. Maturitas, 117, 6-10. PMID 30314563
  • Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011. PMID 26444994
  • Mangione, C. M., et al. (2022). Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA, 328(17), 1740-1746. PMID 36318127
  • Santoro, N., et al. (2021). The Menopause Transition: Signs, Symptoms, and Management Options. Journal of Clinical Endocrinology & Metabolism, 106(1), 1-15. PMID 33095879
  • Hale, G. E., et al. (2009). Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause. Best Practice & Research Clinical Obstetrics & Gynaecology, 23(1), 7-23. PMID 19046657
  • Hale, G. E., et al. (2014). The perimenopausal woman: endocrinology and management. Journal of Steroid Biochemistry and Molecular Biology, 142, 121-131. PMID 24134950
  • Harlow, S. D., et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology & Metabolism, 97(4), 1159-1168. PMID 22344196
  • Crandall, C. J., et al. (2023). Management of Menopausal Symptoms: A Review. JAMA, 329(5), 405-420. PMID 36749328
  • Furness, S., et al. (2012). Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database of Systematic Reviews, 2012(8), CD000402. PMID 22895916
  • Davison, S. L., et al. (2005). Androgen levels in adult females: changes with age, menopause, and oophorectomy. Journal of Clinical Endocrinology & Metabolism, 90(7), 3847-3853. PMID 15827095
  • Zumoff, B., et al. (1995). Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. Journal of Clinical Endocrinology & Metabolism, 80(4), 1429-1430. PMID 7714119
  • Wierman, M. E., et al. (2014). Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 99(10), 3489-3510. PMID 25279570
  • Parish, S. J., et al. (2021). International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine, 18(5), 849-867. PMID 33814355
  • Islam, R. M., et al. (2019). Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes & Endocrinology, 7(10), 754-766. PMID 31353194
  • LeFevre, M. L., et al. (2015). Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 162(9), 641-650. PMID 25798805
  • Sowers, M., et al. (2003). Thyroid stimulating hormone (TSH) concentrations and menopausal status in women at the mid-life: SWAN. Clinical Endocrinology, 58(3), 340-347. PMID 12608940
  • Garber, J. R., et al. (2012). Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid, 22(12), 1200-1235. PMID 22954017
  • El Khoudary, S. R., et al. (2020). Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation, 142(25), e506-e532. PMID 33251828
  • Davidson, K. W., et al. (2021). Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA, 326(8), 736-743. PMID 34427594
  • Pinkerton, J. V. (2022). Concerns About Compounded Bioidentical Menopausal Hormone Therapy. Cancer Journal, 28(3), 241-245. PMID 35594471
  • Stanczyk, F. Z., et al. (2021). Bioidentical hormones. Climacteric, 24(1), 38-45. PMID 33403887
  • Manley, K., et al. (2024). Management of unscheduled bleeding on HRT: A joint guideline on behalf of the British Menopause Society, Royal College Obstetricians and Gynaecologists, British Gynaecological Cancer Society, British Society for Gynaecological Endoscopy, Faculty of Sexual and Reproductive Health, Royal College of General Practitioners and Getting it Right First Time. Post Reproductive Health, 30(2), 95-116. PMID 38743767
  • Clarke, M. A., et al. (2018). Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Internal Medicine, 178(9), 1210-1222. PMID 30083701